| | 1256580-46-7 Basic information More.. |
| Product Name: | Alectinib | | Synonyms: | AF-802;CH-5424802/RG-7853;Alectinib;AF-802,RG-7853;9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile Alectinib (CH5424802);CH5424802-alectinib;9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
CH5424802;CH5424802, Alectinib, AF802 | | CAS: | 1256580-46-7 | | MF: | C30H34N4O2 | | MW: | 482.62 | | EINECS: | 821-541-6 | | Mol File: | 1256580-46-7.mol |  |
Use
Alectinib (Alecensa(R), Roche) was approved first in Japan in 2014 and then by US FDA in 2015 as a second-generation ALK inhibitor for NSCLC treatment on patients who have progressed or do not tolerate crizotinib. Developed through a structure-based drug design approach, alectinib is a benzocarbazolone derivative that has shown potent inhibitory activity against ALK (IC50 value of 1.9 nM) and gatekeeper mutant L1196M ALK (IC50 value of 1.6 nM). Alectinib is effective with crizotinib-resistant ALK mutations on L1196M, F1174L, R1275Q, and C1156Y. In addition, an array of small-molecule inhibitors are currently being evaluated by several clinical trials for ALK-driven tumors.
- Ophtamedine
-
- US $0.00 / KG
- 2025-02-21
- CAS:1256580-46-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
- Alectinib
-
- US $0.00 / Kg/Bag
- 2025-02-12
- CAS:1256580-46-7
- Min. Order: 1KG
- Purity: 99%min
- Supply Ability: 500kgs
- Alectinib
-
- US $0.00 / g
- 2025-01-13
- CAS:1256580-46-7
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
|
|
1256580-46-7
Recommend Suppliers |
|